HC Wainwright Weighs in on Cabaletta Bio FY2029 Earnings

Cabaletta Bio, Inc. (NASDAQ:CABA) – Equities research analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of Cabaletta Bio in a report issued on Tuesday, April 1st. HC Wainwright analyst D. Tsao forecasts that the company will post earnings of ($2.00) per share for the year. HC Wainwright currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Cabaletta Bio’s current full-year earnings is ($2.34) per share.

A number of other equities research analysts have also commented on CABA. Wells Fargo & Company dropped their price objective on shares of Cabaletta Bio from $6.00 to $3.00 and set an “equal weight” rating on the stock in a report on Tuesday. Guggenheim restated a “buy” rating and issued a $23.00 price target on shares of Cabaletta Bio in a report on Tuesday. Evercore ISI downgraded Cabaletta Bio from an “outperform” rating to an “inline” rating and decreased their price objective for the stock from $15.00 to $6.00 in a report on Friday, December 20th. Morgan Stanley dropped their target price on Cabaletta Bio from $30.00 to $22.00 and set an “overweight” rating on the stock in a research report on Tuesday. Finally, UBS Group reduced their price target on Cabaletta Bio from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $22.00.

Cabaletta Bio Stock Performance

Shares of CABA opened at $1.24 on Thursday. The firm has a market cap of $60.61 million, a P/E ratio of -0.58 and a beta of 2.58. Cabaletta Bio has a twelve month low of $1.16 and a twelve month high of $19.04. The firm’s 50 day moving average price is $2.03 and its two-hundred day moving average price is $2.92.

Institutional Investors Weigh In On Cabaletta Bio

Institutional investors and hedge funds have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in Cabaletta Bio during the third quarter worth $32,000. Point72 DIFC Ltd acquired a new position in shares of Cabaletta Bio during the 3rd quarter worth about $33,000. Intech Investment Management LLC bought a new stake in shares of Cabaletta Bio in the 3rd quarter valued at about $67,000. Miller Financial Services LLC acquired a new stake in Cabaletta Bio in the 4th quarter valued at about $33,000. Finally, Avanza Fonder AB bought a new position in Cabaletta Bio during the fourth quarter worth about $40,000.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.